True NorthHealth Labs Build
Peptide Answers

compound

LL-37 (5 mg Vial) Questions Answered

LL‑37 (human cathelicidin) is a multifunctional host‑defense peptide with broad antimicrobial, immunomodulatory, and pro‑healing properties [1] [2] [3] .

Read full protocol Calculate dose Find supplies TNHL ebooks
Educational reference only. TNHL does not diagnose, prescribe, or replace care from a licensed professional. Confirm all dosing, contraindications, and product decisions with qualified guidance.
Direct answer

LL-37 (5 mg Vial)

Route/Frequency: Subcutaneous, once daily . Published human regimens have primarily used topical or intralesional LL‑37; a standardized subcutaneous systemic regimen has not been established [4] [5] [7] .

Quickstart Highlights

LL‑37 (human cathelicidin) is a multifunctional host‑defense peptide with broad antimicrobial, immunomodulatory, and pro‑healing properties [1] [2] [3] .

Standard / Gradual Approach (3.0 mL = ~1.67 mg/mL)

Route/Frequency: Subcutaneous, once daily . Published human regimens have primarily used topical or intralesional LL‑37; a standardized subcutaneous systemic regimen has not been established [4] [5] [7] .

Supplies Needed

Plan based on an 8–16 week once‑daily framework with gradual titration. Peptide Vials (LL‑37, 5 mg each): 8 weeks ≈ 2 vials 12 weeks ≈ 4 vials 16 weeks ≈ 5 vials Insulin Syringes (U‑100): Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syring...

Important Notes

Practical considerations and safety context. Use a new sterile insulin syringe for each administration; dispose in a proper sharps container.